GW&K Increases Stake in Tandem Diabetes Care

Summary

GW&K Investment Management LLC increased its stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 34.9% in Q1, acquiring 740,499 shares, bringing its total to 2,863,987 shares valued at approximately $54.87 million. Other institutional investors also raised their positions. Analysts have mixed ratings on TNDM, with a consensus rating of ‘hold’ and an average target price of $32.71. The stock opened at $14.77, with a 12-month range of $14.66 to $47.60, and reported a quarterly loss of $0.67 EPS, missing estimates.Market Beat

Impact Analysis

This is a company-level event with possible implications at the industry level due to the focus on diabetes care. The increase in GW&K’s stake suggests confidence in Tandem Diabetes Care’s long-term prospects, despite its current financial struggles, highlighted by a quarterly EPS loss of $0.67 and its stock price at a low end of its 12-month range. The investment aligns with other institutional investors increasing their positions, which may stabilize the stock price and could trigger future gains if the company’s performance improves. The consensus ‘hold’ rating and target price of $32.71 indicate that analysts see potential upside mostly reliant on future earnings improvements.Market Beat